24Sep 2022
A Randomized Placebo‐Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR RCT): Primary Efficacy and Safety Findings

A Randomized Placebo‐Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR RCT): Primary Efficacy and Safety Findings

To assess efficacy, safety, pharmacokinetics, and immunogenicity of pegloticase+methotrexate (MTX) vs. pegloticase+placebo (PBO) co‐treatment in a randomized, controlled, double‐blind trial. MTX co‐therapy markedly increased pegloticase response rate over PBO (71.0% vs. 38.5%) during Month‐6 with no new safety signals. These findings verify higher treatment response rate, lower IR incidence, and lower immunogenicity when pegloticase is co‐administered with MTX.

  • #orthopaedics

Like

Save

Share